there were 939 atherosclerotic events in the clopidogrel group during 17,636 patient-years at risk, an average rate per year of 5.32%
there were 1031 events in the aspirin group during 17,519 patient-years risk, an average rate per year of 5.83%
the relative risk reduction was 8.7% (95% CI 0.3-16.5) in favour of clopidogrel (p=0.043)
there was no significant differences between aspirin and clopidogrel in relation to the risk of death from any cause
calculating the number to needed to treat from the CAPRIE trial data, it would be necessary to use clopidogrel instead of aspirin in approximately 200 patients for 1 year to avert one additional major clinical event
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page